not used title
not used title
Maryland may have been the first state in the country to establish a so-called prescription drug affordability board (PDAB), but Marylanders will unfortunately continue to see the failures of government price setting as the board progresses.
In 2019, Maryland created this board and authorized it to develop a state action plan. Bureaucrats who run the board are on the verge of sharing a draft action plan that recommends price setting, but it’s important to know there are more effective ways to deliver cost savings at the pharmacy counter than government price setting.
Since its inception, the PDAB has cost over $3.2 million and hasn’t saved Maryland patients one cent.
Maryland should focus on lowering costs for patients. That can’t be accomplished without addressing the role pharmacy benefit managers (PBMs) play in increasing costs for patients. PBMs decide what medicines people can get and what they pay out of pocket.
1. Only three PBMs control 80% of the entire national market share. What's worse, each of the big PBMs are owned by massive health conglomerates that also own the largest insurance companies and their own pharmacies. Where is the competition? Where is the check and balance? As studies have shown, health insurers and their PBMs are shifting costs to patients through coinsurance and deductibles, choosing profits over patients. It’s unfair to patients. There have been Congressional inquiries along with an ongoing investigation from the Federal Trade Commission into the PBM industry’s questionable practices.
2. Patients need lower out-of-pocket costs without a reduction in health care choice, quality, or access. If patients can’t access or afford their treatments, the system doesn’t work. Biopharmaceutical research companies pay billions in negotiated rebates and discounts annually (approximately $256 billion in 2022) to insurers and PBMs. These discounts lower what insurers pay, but patients are often forced to pay based on the full price.
Despite manufacturers’ rebates and discounts negotiated by health plans that have kept price increases below inflation for the last five years, nearly half of commercially insured patients’ out-of-pocket spending for brand medicines is based on the medicine’s undiscounted list price.
3. PBM compensation reform could prevent PBMs from skirting regulation on rebates. PBMs should receive a fixed fee based on the value of services they provide instead of tying their compensation to the list price of a medicine. This is a way Maryland can stop PBMs from gaming the system. There are many fee-for-service PBMs in the market, doing the right thing for patients and passing 100% of the rebates on to the patient, where they’re needed most.
4. Requiring PBMs to act in the best interest of their plans, providers, and patients would be an important step for state legislatures to take. In other words, Maryland should hold PBMs accountable so that they act in a transparent manner and place their duties to patients, providers, and their clients before their own financial interests.
While well-intentioned legislators are hoping to reduce patient costs, this board does not achieve that goal. There is no specification as to how the state could track or monitor savings for out-of-pocket costs or ensure the lowest prices reach Marylanders.
State lawmakers in Maryland can join members of Congress and other states looking to fix the broken PBM model and help patients. Learn more about how West Virginia, Arkansas, and Indiana are already leading the way to lower costs for patients at the pharmacy.
Stami Turk
Stami Williams is Director of State Public Affairs where she oversees earned and paid media efforts in several regions across the country. Stami received her M.P.S. from George Washington University, where she remains an adjunct professor with undergraduate studies at Kennesaw State University in Georgia.
Stami Turk
New poll: 2 in 3 voters prefer a candidate committed to lowering health insurance premiums
September 18, 2026
What AARP isn’t telling seniors about MFN
August 24, 2026
Policymakers should improve patient access and reject price controls
August 18, 2026
Insurers blame GLP-1s for rising costs. The data tells a different story.
August 14, 2026
The FTC’s PBM enforcement actions gave us a glimpse behind the curtain; it’s time to let the light in.
August 7, 2026
Nearly 1 in 4 patients initially denied access to IRA medicines
August 6, 2026
Message to USAging: Providers are raising concerns about coverage barriers
July 22, 2026
New PBM principles don't change the fundamental challenge: Access to lower-cost medicines
July 10, 2026
340B’s reality: A booming business for hospitals, pharmacies and corporate giants
June 25, 2026
Insurers are blaming medicines for premium hikes in Massachusetts. The state's own data suggests otherwise.
June 24, 2026
Briefing: Capitol Hill panel on "Healthcare Denial Crisis in America"
April 24, 2026
Survey confirms too many insured Americans face barriers to reliable health care
April 22, 2026
70% DENIED: How insurance denials are delaying and preventing care for millions of Americans
April 14, 2026
Hospitals drive nearly 80% of the U.S. health spending gap
March 25, 2026
No hassle, hidden markups or fees: AmericasMedicines.com
February 19, 2026
The Federal Trade Commission (FTC) takes important action to highlight and curb PBM abuses
February 17, 2026
Separating fact from fiction in the medicine supply chain
February 11, 2026
50-state poll says Americans are concerned that hospital markups hurt patients
January 27, 2026
Three things you should know from the insurer CEO congressional hearings
January 26, 2026
Can’t get your medicine? Don’t count on your insurer.
January 15, 2026
Stop, collaborate and re-evaluate: ICER’s pricing report
November 14, 2025
California’s landmark PBM crackdown: A wake-up call for reform
November 13, 2025
Middlemen mark up drug prices and keep discounts meant for you
November 10, 2025
Putting patients first: Breaking down barriers to care
October 28, 2025
Direct purchase programs can lower costs for patients
October 20, 2025
PBMs say they want lower priced medicines, so why don’t they cover them?
October 7, 2025
Historic biopharmaceutical investments: A prescription for America’s future
September 29, 2025
Why states struggle to deliver savings: Middlemen and 340B siphon dollars from patients and states
September 15, 2025
PBMs are hiding hurdles to essential care
August 20, 2025
New study: PBMs and commercial insurers are quietly blocking prescription access
July 30, 2025
North Carolina puts patients first with rebate pass-through law
July 29, 2025
PBMs, not patents, are blocking access to lower-cost medicines
July 23, 2025
Medicare Part D plans initially denied medicines for more than 70% of patients in four chronic disease areas
June 16, 2025
New “Balance the Scales” campaign highlights why Americans pay more for prescription medicines
May 21, 2025
How the 340B hospital markup program and PBMs drive up costs for U.S. patients
May 16, 2025
Foreign first pricing schemes don’t address why Americans pay more
May 15, 2025
The AHIP premium dollar corrected (again)
May 8, 2025
PBMs launch new ad campaign to block reforms
May 5, 2025
When middlemen own it all, patients pay the price
April 10, 2025
3 myths critics get wrong about intellectual property
March 28, 2025
New report finds more abuse of 340B program by hospitals and drug middlemen
March 24, 2025
A closer look at how health care consolidation drives up patient costs, creates barriers to care
March 17, 2025
Health care practitioners sound the alarm on middlemen-imposed barriers to patient care, need for policy change
March 13, 2025
Congress Keeps PBMs in the Hot Seat
March 6, 2025
Biopharmaceutical innovation for a healthier America: PhRMA releases new innovation report
February 21, 2025
New policy agenda charts solutions for a healthier America
February 20, 2025
A successful PhRMA Forum highlights our commitment to a healthier America
February 20, 2025
Wrapping up the J.P. Morgan Healthcare Conference
January 16, 2025
FTC finds PBMs make billions in profit from marking up cancer, other critical generic drugs
January 14, 2025
PhRMA CEOs Tee Up Next Week's Health Care Conference
January 11, 2025
New study: Entities that don’t make medicines get half of what is spent on those medicines
January 7, 2025
Three things to know about 340B contract pharmacies
November 12, 2024
The PBM industry's desperate attempt to stop reform
November 12, 2024
PhRMA launches new ad calling for Congress to make sure savings go to patients, not PBMs
November 11, 2024
Reimagining patient access through meaningful policy reform
November 5, 2024
ICYMI: Grounding policy reforms in real lived patient experiences is key to improving outcomes
October 31, 2024
New PES survey: Out-of-pocket costs lead key health care priorities ahead of the November election
October 30, 2024
Guest Post: My health care vote
October 29, 2024
Insurers continue shifting more costs on to patients
October 28, 2024
Americans speak out on health insurance barriers and need for policy change, according to the latest Patient Experience Survey
October 28, 2024
ICYMI: The powerful companies driving local drugstores out of business
October 25, 2024
Hispanic Heritage Month: Fighting for Hispanic patients
October 7, 2024
PBMs and insurers off the hook: Sen. Sanders’ selective hearing on drug costs
September 24, 2024
Key voter insights two months from Election Day
September 10, 2024
Patient priorities in the 2024 election
September 10, 2024
Don’t put the government between patients and their medicines
August 7, 2024
Voters across all 50 states want state policymakers to focus on health insurance and PBM practices
July 30, 2024
WTAS: Voters voice concerns about PBM abuses, call on policymakers to act
July 19, 2024
PhRMA launches new ad in campaign exposing ways middlemen drive up costs
July 17, 2024
FTC report confirms PBMs profit at the expense of patients
July 10, 2024
New 50-state poll Americans want to hold health insurers and PBMs accountable for high out-of-pocket costs and other practices
July 9, 2024
ICYMI: Hidden markups at mail-order pharmacies increase costs for employers
July 2, 2024
The IRA could lead to higher out-of-pocket costs for 3.5 million Medicare patients in 2026
June 25, 2024
ICYMI: What patients care about this election year
June 24, 2024
ICYMI: The Opaque Industry Secretly Inflating Prices for Prescription Drugs
June 21, 2024
ICYMI: Health care policy should be driven by patients, not politics
June 10, 2024
PhRMA Warns Federal Agencies: Consolidation and vertical integration among insurers, PBMs, and hospitals threaten patients
June 5, 2024
ICYMI: Innovation transforms lives but misguided federal policies threaten patient outcomes
May 30, 2024
Ongoing federal probes shed light on PBM and insurer practices
May 20, 2024
WTAS: The consequences of consolidation and vertical integration
May 6, 2024
Insurance data: PBM reform has no material impact on premiums
April 24, 2024
ICYMI: Voter priorities this election season
April 18, 2024
New study finds insurers and PBMs increasing access restrictions in Medicare Part D
April 16, 2024
3 Takeaways from POLITICO’s Health Care Summit
April 3, 2024
PBMs using 340B program to drive profits at patients’ expense
March 28, 2024
Setting the Record Straight: Comparing U.S. drug prices to those in foreign countries hurts patients
February 7, 2024
When it comes to the future of innovation, the ball is in policymakers’ court
January 22, 2024
How the 340B program became a PBM giveaway
December 11, 2023
ICYMI: When middlemen get in the way, it’s the patients who lose
December 5, 2023
Get the facts on PCMA’s newest attempt to avoid accountability
December 4, 2023
The IRA’s pill penalty threatens the future of oncology R&D
November 16, 2023
ICYMI: WSJ — Same Drug, Two Prices: Why the Higher Price Prevails
November 15, 2023
ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference
November 6, 2023
One year to Election Day: Four voter priorities to watch
November 6, 2023
ICYMI: Scott LaGanga and Matt Salo deliver a State of the Industry Report
October 25, 2023
New poll shows strong bipartisan support for PBM reform
October 20, 2023
4 truths about state government price setting
October 10, 2023
ICYMI: Government watchdog report finds patients in Medicare Part D paid billions more for medicines than insurers and PBMs
September 28, 2023
Word of the Month: AMR
September 27, 2023
Medicare Prescription Payment Plan will benefit patients if implemented correctly
September 21, 2023
New analysis shows PBMs use fees as a profit center
September 18, 2023
It’s PBMs, not patents, blocking competition
September 14, 2023
New PhRMA ad exposes yet another way PBMs get between patients and their medicines
September 5, 2023
Navigating the Patient Experience Survey: Protecting Lifelines to Access and Innovation
July 26, 2023
Three things to know from the latest Patient Experience Survey
July 20, 2023
More than 60 researchers ask Congress to support innovation
June 26, 2023
ICYMI: PBM exec admits choosing profits over patients
June 2, 2023
Insulin: Key Facts on Access & Affordability
May 10, 2023
4 key facts on medicine prices and spending
May 9, 2023
4 Things to know about PhRMA’s new 50-state poll
May 4, 2023
Americans want state policymakers to lower out-of-pocket costs
May 1, 2023
New PhRMA ad campaign sheds light on PBM abuses
May 1, 2023
Policies need to address the growing threat of antimicrobial resistance
April 28, 2023
Three facts about health care spending
April 25, 2023
AHIP’s latest misinformation campaign & what it’s trying to hide
April 24, 2023
New global analysis shows patient access challenges around the world
April 12, 2023
ICYMI: PhRMA President and CEO Stephen J. Ubl discusses patient affordability
April 7, 2023
States can support access to medicine as COVID-19 Public Health Emergency ends
April 5, 2023
Arkansas puts patients first with new share the savings law
April 4, 2023
Key Trends: Patient experience data reveal how insurers and middlemen impose barriers in health care
March 29, 2023
Insurer and PBM tactics are shifting higher costs to patients with chronic and complex conditions
March 2, 2023
Holding pharmacy benefit managers accountable
February 23, 2023
Stopping pharmacy benefit managers from “gaming the system”
February 22, 2023
Senate hearing to examine bipartisan reforms to rein in middlemen
February 16, 2023
Minnesota lawmakers are letting PBMs off the hook, and threatening patients’ access to medicines
January 31, 2023
ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference
January 19, 2023
ICYMI: PhRMA COO Lori Reilly speaks about the health care agenda for the next Congress
December 9, 2022
In their own words: Financial barriers exacerbate access challenges for insured Americans
December 8, 2022
Putting Delaware patients first: Protecting Patient Assistance Programs
November 22, 2022
New data show how insurers and middlemen shift Rx costs onto patients
November 16, 2022
In their own words: Insured Americans struggle to navigate complex coverage
October 26, 2022
Many seniors are paying more for Part D medicines than their insurer
October 18, 2022
New comments outline ways to protect patients from health plans and PBMs who profit from patient assistance
October 7, 2022
Busting 3 Myths About Copay Coupons
October 5, 2022
Mental Illness Awareness Week – A time for reflection
October 3, 2022
A key fact the White House is reluctant to admit
September 27, 2022
A key fact the White House is reluctant to admit
September 27, 2022
Navigating the patient experience: Burdens and barriers standing between patients and their care
September 12, 2022
Making coupons count for patients at the pharmacy counter
August 25, 2022
Insulin and reconciliation
August 15, 2022
New survey: Voters seriously concerned about fine print in reconciliation bill
August 12, 2022
Making coupons count for patients with HIV
August 8, 2022
Myth vs. Fact: The Senate’s latest price setting proposal
August 5, 2022
The Senate’s latest price setting proposal will undermine U.S. economic growth
August 3, 2022
Celebrating Medicare’s 57th anniversary
August 2, 2022
New analysis finds deeper impact of drug pricing bill on biopharmaceutical researchers
August 1, 2022
The Senate’s latest price setting proposal will undermine: Our health care system
July 28, 2022
The Senate’s latest price setting proposal will undermine: American medical innovation
July 27, 2022
The Senate’s latest price setting proposal will undermine: Patient access to medicines
July 26, 2022
Survey Says: Prescription drug prices are not fueling inflation concerns for Americans
July 22, 2022
The Patient Perspective: Government price-setting harms patients
July 22, 2022
Putting patients first at the state level — A conversation with Mark Reisenauer, President of Astellas Pharma US
July 14, 2022
Polling continues to show voters reject so-called Medicare “negotiation” once they learn about consequences for patients
July 12, 2022
By the Numbers: Patients lose when the government sets prices
July 8, 2022
Patients win as West Virginia implements first-in-nation share the savings policy
July 8, 2022
3 things voters are concerned about when it comes to their health care coverage
July 7, 2022
Copay assistance is a lifeline for patients. So why are insurers blocking it?
June 29, 2022
Patients support state action requiring PBMs and insurers to share savings and cap costs for medicines
June 16, 2022
New poll shows voters sounding the alarm on health insurance companies and PBMs
June 6, 2022
PhRMA warns of the growing influence of middlemen over patient access and out-of-pocket costs for patients
May 31, 2022
ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond
May 9, 2022
Study finds insurance barriers disproportionately burden patients with chronic illness
May 4, 2022
Three charts show how the Medicare Part D program could be improved to work better for seniors and people with disabilities
April 27, 2022
What’s really happening when it comes to prescription drug costs
April 27, 2022
5 public opinion polling trends to watch
April 22, 2022
Analysis: States can help patients save nearly $1,000 annually on their medicines
April 21, 2022
New analysis confirms hospitals markup prices for oncology therapies
April 21, 2022
How standardized plans can improve patients’ access to medicines
April 18, 2022
The patient experience: Uncovering the barriers to care for insured Americans
March 28, 2022
Correcting the record: Putting medicine costs and spending in context
March 24, 2022
Sharing rebates can save Americans with diabetes 500 each year and improve adherence
March 16, 2022
Veterans Affairs 101: Three charts show how the VA system differs from Medicare
March 11, 2022
If drug prices are growing below the rate of inflation, why are patients still feeling the sting at the pharmacy?
March 8, 2022
The patient experience: Insurance barriers continue to impede access to health care, especially among the country’s underserved
February 28, 2022
Government price setting leaves behind families counting on new medicines
February 23, 2022
PhRMA submits comments urging CMS to withdraw coverage proposal
February 11, 2022
Medicaid 101: Three charts on access and spending
February 3, 2022
Government price setting won’t stop insurers from shifting costs to patients
February 2, 2022
New comments outline ways to counteract cost-shifting insurance trends
January 28, 2022
Patients need to pay less for their medicines. States can help.
January 26, 2022
It’s a new year, but sadly Congress is still pursuing flawed price setting policies
January 25, 2022
New poll of all 50 states and 435 Congressional Districts shows perils of so-called Medicare “negotiation”
January 25, 2022
New study finds more than half of brand medicine spending goes to the supply chain and others
January 7, 2022
Making medicines more affordable: Preserving safety-net programs like 340B
December 17, 2021
Post-approval research save lives. Why is Congress trying disincentivize it?
December 17, 2021
A price control by any other name would still put patients at risk and threaten innovation
December 9, 2021
Making medicines more affordable: Making insurance work like insurance
December 8, 2021
Navigating the patient experience in the time of COVID-19
December 6, 2021
Insurance design barriers can impact patient adherence and can lead to poor health outcomes
November 23, 2021
What is missing in the current drug pricing plan
November 23, 2021
ICYMI: PhRMA CEO speaks at STAT Summit about government price setting
November 19, 2021
Making medicines more affordable: Sharing savings at the pharmacy counter
November 19, 2021
Three things to know about so-called Medicare negotiation polling
November 18, 2021
Making Medicines More Affordable: Making coupons count
November 5, 2021
What they are saying: Government price setting for medicines is not the answer
November 4, 2021
Four things to know from IQVIAs latest report
October 29, 2021
The patient experience: Insurance design hurdles lead to access issues for too many Americans
October 28, 2021